Pharmacodynamics describes what a drug does to the body, beginning with the interaction between the drug molecule and its molecular target. For the vast majority of drugs, the primary target is a receptor -- a protein whose normal function is to respond to endogenous ligands and transduce signals into cellular responses. The type of receptor a drug acts on determines not only the nature of the pharmacological response but also its speed of onset, its intracellular mechanisms, and its potential for regulation and adaptation.
G protein-coupled receptors (GPCRs) are the largest and most pharmacologically important family of drug targets, comprising over 800 human genes and mediating the effects of an enormous range of drugs across virtually every therapeutic area. GPCRs are integral membrane proteins with seven transmembrane-spanning alpha-helical domains; when activated by an agonist, they couple to heterotrimeric G proteins (composed of Galpha, Gbeta, and Ggamma subunits) that dissociate upon receptor activation and regulate downstream effectors. The Gs alpha subunit (stimulatory) activates adenylyl cyclase to increase cyclic adenosine monophosphate (cAMP); the Gi alpha subunit (inhibitory) inhibits adenylyl cyclase; the Gq alpha subunit activates phospholipase C (PLC) to generate inositol trisphosphate (IP3) and diacylglycerol (DAG), which release intracellular calcium and activate protein kinase C (PKC) respectively. Drugs acting through GPCRs include beta-adrenergic agonists and antagonists (beta-1 and beta-2 adrenoceptors, Gs-coupled), muscarinic agonists and antagonists (five muscarinic receptor subtypes, variably coupled to Gq and Gi signaling pathways), opioid agonists and antagonists (mu, kappa, delta receptors, Gi-coupled), and dopamine receptor drugs (D1 (dopamine receptor 1) family Gs-coupled; D2 (dopamine receptor 2) family Gi-coupled).1
Ligand-Gated Ion Channels. Ligand-gated ion channels (LGICs) are membrane proteins that open or close in direct response to ligand binding, producing rapid changes in membrane potential or ion flux without second messenger intermediaries. The speed of response (milliseconds) makes them the predominant receptor type at fast synapses. The nicotinic acetylcholine receptor (nAChR) is the prototype: binding of two acetylcholine (ACh) molecules opens a cation channel permeable to sodium (Na+) and potassium (K+), producing depolarization and the neuromuscular junction action potential. Clinically important LGIC (ligand-gated ion channel) targets include the gamma-aminobutyric acid type A (GABA-A) receptor (a chloride-permeable channel potentiated by benzodiazepines and barbiturates), the N-methyl-D-aspartate (NMDA) receptor (a glutamate-gated cation channel blocked by ketamine and memantine), and the glycine receptor (a chloride channel blocked by strychnine). Voltage-gated ion channels, though not technically ligand-gated, are also pharmacologically important targets: local anesthetics and antiarrhythmics act on voltage-gated sodium (Nav) channels, and many cardiovascular drugs act on voltage-gated calcium (Cav) and potassium (Kv) channels.12
Enzyme-Linked Receptors and Intracellular Enzymes. Enzyme-linked receptors are transmembrane proteins whose cytoplasmic domain has intrinsic enzymatic activity, most commonly tyrosine kinase activity, activated by ligand binding at the extracellular domain. Receptor tyrosine kinases (RTKs) mediate the effects of many growth factors and cytokines and are the targets of a growing class of small-molecule kinase inhibitor drugs (the "-nib" class: imatinib, erlotinib, sunitinib) used extensively in oncology. The insulin receptor is an RTK (receptor tyrosine kinase) whose activation triggers the downstream phosphatidylinositol 3-kinase (PI3K)/Akt pathway governing glucose uptake. Some drugs bypass surface receptors entirely by acting on intracellular enzymes: statins inhibit 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase in the cholesterol synthesis pathway, methotrexate inhibits dihydrofolate reductase (DHFR), and aspirin irreversibly acetylates cyclooxygenase (COX) enzymes.1
Nuclear Receptors. Nuclear receptors are ligand-activated transcription factors that, once bound by their lipophilic ligand, translocate to the nucleus and regulate gene expression directly by binding to specific DNA (deoxyribonucleic acid) response elements in the promoter regions of target genes. Because the response requires new protein synthesis, the onset of pharmacological action is slow (hours to days) compared to GPCR (G protein-coupled receptor) and ion channel-mediated effects. The nuclear receptor superfamily includes the glucocorticoid receptor (GR), mineralocorticoid receptor (MR), thyroid hormone receptor (TR), estrogen receptor (ER), androgen receptor (AR), peroxisome proliferator-activated receptor (PPAR), and retinoic acid receptor (RAR). All glucocorticoid drugs (prednisone, dexamethasone, budesonide), thyroid hormone analogs, sex hormone drugs, fibrates (PPAR-alpha agonists), and thiazolidinediones (PPAR-gamma agonists) act via nuclear receptors. The slow onset and genomic mechanism account for the delayed clinical effects of these drug classes -- the anti-inflammatory effect of a corticosteroid dose is not fully manifest for 6-12 hours, a clinically important fact when selecting routes and doses for acute conditions.2
Ligand-gated ion channels (nAChR, GABA-A, NMDA): milliseconds -- fast synaptic transmission. GPCRs: seconds to minutes -- second messenger amplification cascades. Receptor tyrosine kinases: minutes to hours -- phosphorylation cascades and altered enzyme activity. Nuclear receptors: hours to days -- new gene transcription and protein synthesis required. This gradient has direct clinical implications: a patient in anaphylaxis needs epinephrine (GPCR, seconds) not a corticosteroid (nuclear receptor, hours).
The pharmacological classification of a drug as an agonist, antagonist, or something in between depends on two independent properties: affinity (how strongly it binds to the receptor) and efficacy (what it does to the receptor once bound). Understanding these concepts is essential for predicting drug effects, interpreting clinical trial data, and managing competitive and non-competitive drug interactions.
Affinity and Efficacy. Affinity is the strength of binding between a drug and its receptor, quantified by the equilibrium dissociation constant (Kd): the drug concentration at which 50% of receptors are occupied. A lower Kd indicates higher affinity -- the drug binds more tightly and at lower concentrations. Efficacy (intrinsic activity) describes the ability of the drug-receptor complex to produce a biological response. Efficacy is an intrinsic property of the drug-receptor interaction and is distinct from potency (which describes the concentration required to produce a given effect). A drug can have high affinity for a receptor but zero efficacy -- this defines a competitive antagonist. A drug with high affinity and maximal efficacy is a full agonist. These distinctions matter clinically: two full agonists at the mu-opioid receptor (e.g., morphine and fentanyl) may differ substantially in potency (fentanyl is approximately 100 times more potent) but both produce maximal analgesia if given at sufficient doses, while a partial agonist (buprenorphine) produces a ceiling effect regardless of dose.14
Full Agonists, Partial Agonists, and Inverse Agonists. A full agonist binds to the receptor and produces the maximal possible response (Emax = 100% of the system maximum). A partial agonist binds and activates the receptor but produces a submaximal response even at receptor saturation -- its intrinsic activity is between 0 and 1 relative to the full agonist reference. Partial agonists can behave as agonists when no full agonist is present, but as functional antagonists when competing with a full agonist for the same receptor. Buprenorphine is a clinically critical example: it has very high affinity for the mu-opioid receptor with partial agonist activity, making it useful for opioid dependence treatment (provides some mu activation to prevent withdrawal) and effective in reversing overdose caused by lower-affinity full agonists. An inverse agonist binds to the receptor and actively reduces activity below the baseline constitutive activity level; several antihistamines (H1 (histamine receptor 1) receptor inverse agonists rather than simple antagonists) and some beta-blockers with inverse agonist activity fall into this category.1
Competitive and Non-Competitive Antagonism. A competitive antagonist binds reversibly to the same site as the agonist (the orthosteric site) and blocks agonist access in a concentration-dependent manner. Competitive antagonism is surmountable: increasing the agonist concentration can overcome the antagonist and restore the maximal response, though a higher agonist concentration is required. On a log dose-response curve, competitive antagonism produces a parallel rightward shift in the agonist curve without reduction in Emax. The degree of rightward shift quantifies the antagonist's potency and is the basis of the Schild analysis. Non-competitive antagonism occurs when an antagonist binds to an allosteric site (distinct from the agonist binding site) or binds irreversibly to the orthosteric site, reducing Emax regardless of agonist concentration. Non-competitive antagonism cannot be overcome by increasing agonist dose -- the maximum achievable response is reduced. Phenoxybenzamine, an irreversible non-competitive alpha-adrenoceptor antagonist, illustrates this clinically: its blockade cannot be reversed by increased norepinephrine output, making it reliable for preoperative preparation in pheochromocytoma.12
Potency describes the dose or concentration required to produce a given effect (quantified by EC50, the concentration producing 50% of maximal effect). Efficacy describes the maximal response a drug can produce. These are independent: a drug can be highly potent (active at very low concentrations) but have low efficacy (ceiling effect), or have low potency but full efficacy. Fentanyl is more potent than morphine (lower EC50) but both are full mu-opioid agonists with equivalent efficacy. Buprenorphine has high potency and high affinity but partial efficacy. In clinical practice, potency determines dosing range; efficacy determines the ceiling of therapeutic benefit.
The dose-response relationship is the quantitative foundation of pharmacodynamics, describing how the magnitude of a drug effect changes as the dose or concentration increases. Two distinct types of dose-response curves -- graded and quantal -- provide complementary information about drug action and are used for different purposes in drug evaluation and safety assessment.
Graded Dose-Response Curves. A graded dose-response curve plots drug effect (on a continuous scale, such as heart rate reduction in beats per minute or blood pressure change in mmHg) against drug concentration or dose, typically using a log scale for the x-axis. The resulting sigmoid (S-shaped) curve on a log-dose scale has several characteristic parameters. The maximum effect (Emax) is the plateau of the curve, representing the maximum response achievable regardless of further dose increases; it reflects receptor efficacy. The concentration producing 50% of maximal effect, the EC50 (half maximal effective concentration), is the primary measure of potency: a drug with a lower EC50 is more potent because it produces a given effect at a lower concentration. The slope of the dose-response curve (Hill slope or slope factor) describes how steeply the effect increases with dose; a steep slope means that small dose changes produce large effect changes, which has practical implications for dose titration and safety. The concept of spare receptors (receptor reserve) explains why maximal responses are often achieved when only a fraction of available receptors are occupied: many tissues have more receptors than are needed to achieve Emax, providing a buffer against partial receptor inactivation.15
Quantal Dose-Response Curves. A quantal dose-response curve uses an all-or-none endpoint (the drug either produces the specified effect in a subject or it does not) and plots the cumulative percentage of a population showing the response against log dose. This approach is used when the response cannot be measured on a continuous scale (e.g., death, seizure, loss of consciousness, or pain relief defined as yes/no). The median effective dose (ED50) is the dose producing the specified effect in 50% of subjects, and the median lethal dose (LD50) is the dose causing death in 50% of subjects in animal studies. These quantal parameters form the basis of the therapeutic index (TI), defined as TI = LD50 / ED50 in animal studies. A high TI indicates a large separation between effective and lethal doses and a correspondingly wide margin for error in dosing -- penicillin has a very high TI, making accidental overdose almost impossible. A low TI (narrow therapeutic window) means that the doses required for therapeutic efficacy are close to those causing toxicity -- digoxin, warfarin, lithium, phenytoin, aminoglycosides, and vancomycin all have narrow TIs that require therapeutic drug monitoring (TDM) in clinical practice.56
The Margin of Safety and Therapeutic Window. The margin of safety refines the therapeutic index by using the dose that is lethal in 1% of subjects (LD1) and the dose that is effective in 99% of subjects (ED99): margin of safety = LD1 / ED99. This more conservative calculation accounts for interindividual variability in both the effective and toxic dose distributions. In clinical practice, the therapeutic window is the concentration range between the minimum effective concentration (MEC) and the minimum toxic concentration (MTC). Drugs with narrow therapeutic windows require individualized dosing, therapeutic drug monitoring, and careful attention to pharmacokinetic changes caused by renal or hepatic impairment, drug interactions, and pharmacogenomic variation. The concept of the therapeutic window also underpins modified-release formulations: sustained-release preparations are designed to maintain plasma concentrations within the therapeutic window continuously, avoiding both subtherapeutic troughs and toxic peaks that can occur with conventional immediate-release dosing.56
Digoxin: TDM target 0.5-0.9 ng/mL (heart failure); toxicity risk above 2 ng/mL. Warfarin: INR target varies by indication; interactions via CYP2C9 and CYP3A4 mandate frequent monitoring. Lithium: target 0.6-1.2 mEq/L; toxicity above 1.5 mEq/L; renally cleared, dose-adjust for renal impairment. Phenytoin: target total 10-20 mg/L (free 1-2 mg/L); zero-order kinetics above therapeutic range. Aminoglycosides: target peak and trough concentrations for both efficacy (concentration-dependent killing) and nephrotoxicity avoidance. Vancomycin: target AUC/MIC 400-600 mg-h/L using Bayesian dosing.
The relationship between drug concentration and effect is not static -- repeated drug exposure can alter receptor number, coupling efficiency, and signal transduction pathways, producing either diminished responses (tolerance, desensitization) or enhanced responses (sensitization, up-regulation). Understanding these adaptive mechanisms is essential for managing drug therapies that require long-term use and for anticipating the consequences of abrupt drug discontinuation.
Tachyphylaxis and Rapid Desensitization. Tachyphylaxis is a rapid decrease in response to a drug following initial administration or repeated dosing over a short time period. It is distinct from tolerance, which develops over longer periods, in that tachyphylaxis can occur within minutes to hours. The principal molecular mechanism is receptor desensitization: agonist binding activates G protein-coupled receptor kinases (GRKs) that phosphorylate the intracellular loops of the activated receptor, reducing its coupling efficiency to G proteins, and promotes binding of arrestin proteins that uncouple the receptor from downstream signaling and target it for endocytosis. The clinical prototype is the tachyphylaxis seen with repeated doses of indirect sympathomimetics (ephedrine, amphetamine): these drugs release norepinephrine from nerve terminals, but with each subsequent dose the releasable pool is depleted, and the pressor response diminishes progressively. Direct-acting sympathomimetics (phenylephrine) do not show the same degree of tachyphylaxis because they bypass the releasable norepinephrine pool.34
Long-Term Tolerance and Receptor Down-Regulation. Prolonged agonist exposure can reduce total receptor number through receptor internalization and subsequent lysosomal degradation -- a process called down-regulation. Down-regulation reduces the maximum response achievable at any agonist concentration, corresponding to a reduction in Emax. Beta-adrenoceptor down-regulation occurs in heart failure, where chronically elevated sympathetic tone leads to reduced beta-1 receptor density in cardiac myocytes, reducing inotropic and chronotropic responses to catecholamines. This accounts for the paradoxical clinical benefit of beta-blockers in heart failure: by blocking chronic sympathetic stimulation, they allow beta-receptor density to partially recover (up-regulation during beta-blocker therapy), restoring sensitivity to endogenous catecholamines and improving cardiac responsiveness. Opioid tolerance involves multiple mechanisms beyond receptor down-regulation, including receptor desensitization, reduced G protein coupling, upregulation of adenylyl cyclase (adenylyl cyclase supersensitivity), and changes in downstream ion channel expression.34
Receptor Up-Regulation and Withdrawal Syndromes. Chronic antagonist exposure can produce the opposite effect: receptor up-regulation, an increase in receptor number or sensitivity in response to prolonged blockade of receptor signaling. Up-regulation is the molecular basis for several clinically important withdrawal syndromes. Abrupt discontinuation of beta-blockers in patients with ischemic heart disease is associated with rebound hypertension, tachycardia, and increased risk of myocardial infarction because up-regulated beta-adrenoceptors are suddenly exposed to endogenous catecholamines without pharmacological blockade. Similarly, abrupt discontinuation of clonidine (a central alpha-2 adrenoceptor agonist that reduces sympathetic outflow) causes rebound hypertension from up-regulated peripheral adrenoceptors. Chronic ethanol exposure up-regulates NMDA (N-methyl-D-aspartate) receptors and down-regulates GABA-A (gamma-aminobutyric acid type A) receptors; abrupt alcohol withdrawal unmasks this imbalance, producing glutamate-mediated excitotoxicity manifesting as tremor, seizures, and delirium tremens -- a life-threatening syndrome that requires benzodiazepine treatment to restore inhibitory tone.24
Receptor types determine response speed: LGICs (ms), GPCRs (sec-min), RTKs (min-hr), nuclear receptors (hr-days). Agonist efficacy ranges from full agonist (Emax = 100%) to partial agonist (ceiling below Emax) to inverse agonist (reduces constitutive activity below baseline). Competitive antagonism: surmountable, parallel rightward shift, Emax preserved. Non-competitive: non-surmountable, Emax reduced. TI = LD50/ED50; narrow TI drugs require TDM (digoxin, warfarin, lithium, phenytoin, aminoglycosides, vancomycin). Tolerance: receptor desensitization + down-regulation with chronic agonist exposure. Up-regulation with chronic antagonist exposure -- abrupt withdrawal can cause dangerous rebound (beta-blockers, clonidine, alcohol).
Ritter JM, Flower R, Henderson G, Loke YK, MacEwan D, Rang HP. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2019. ISBN 9780702074486.
ISBN 9780702074486Katzung BG, Trevor AJ, eds. Basic and Clinical Pharmacology. 15th ed. New York: McGraw-Hill; 2021. ISBN 9781260452310.
ISBN 9781260452310Lefkowitz RJ, Shenoy SK. Transduction of receptor signals by beta-arrestins. Science. 2005;308(5721):512-517.
doi:10.1126/science.1109237Gainetdinov RR, Premont RT, Bohn LM, Lefkowitz RJ, Caron MG. Desensitization of G protein-coupled receptors and neuronal functions. Annu Rev Neurosci. 2004;27:107-144.
doi:10.1146/annurev.neuro.27.070203.144206Neubig RR, Spedding M, Kenakin T, Christopoulos A. International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on terms and symbols in quantitative pharmacology. Pharmacol Rev. 2003;55(4):597-606.
doi:10.1124/pr.55.4.4Waller DG, Sampson AP. Medical Pharmacology and Therapeutics. 5th ed. Edinburgh: Elsevier; 2018. ISBN 9780702071676.
ISBN 9780702071676